Gracell Bio Shares Tumble as Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment
Receipt of ‘orphan drug’ designation for company’s CAR-T cancer drug in the U.S. will bring financial incentives, but also underscores drug’s limited market potential Key takeaways Gracell Bio stands to…
RELATED ARTICLES
-
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
GRCL.US -
FAST NEWS: Gracell shareholders approve merger with AstraZeneca
GRCL.US
-
Why JL Mag came unstuck, but is getting back on track
6680.HK 300748.SHE
-
As solar construction in China cools, Hainan Drinda looks for relief overseas
002865.SHE
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
